Back to Search
JAMES NEMUNAITIS, D.O.
D.O.
Sports Medicine (Orthopaedic Surgery) Physician
NPI: 1295185130IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Surgery Physician
Orthopaedic Surgery
Code: 207X00000X
OT016885(PA)
Sports Medicine (Orthopaedic Surgery) PhysicianPrimary
Orthopaedic Surgery — Sports Medicine
Code: 207XX0005X
OS021959(PA)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Class of 2016
Research & Publications (20)
Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
PMID 19086841·Future Oncol·2008
5-case
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
PMID 16410826·Cancer Gene Ther·2006
3-trial
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
PMID 16581300·Mol Ther·2006
3-trial
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
PMID 15897585·Clin Cancer Res·2005
3-trial
A review of contusugene ladenovec (Advexin) p53 therapy.
PMID 19169960·Curr Opin Mol Ther·2009
6-review
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
PMID 19643020·BMC Cancer·2009
3-trial
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
PMID 19536890·Cancer·2009
3-trial
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
PMID 19501491·Clin Oncol (R Coll Radiol)·2009
3-trial
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.
PMID 19275571·Curr Gene Ther·2009
6-review
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
PMID 19385713·Clin Pharmacokinet·2009
4-observational
Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based cancer therapies.
PMID 19085121·Methods Mol Biol·2009
6-review
Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.
PMID 18846113·Cancer Gene Ther·2009
6-review
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
PMID 19287371·Cancer Gene Ther·2009
3-trial
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
PMID 18802154·J Clin Oncol·2008
3-trial
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
PMID 18801509·J Urol·2008
3-trial
Emergency use regulatory approval process for experimental gene-based therapy.
PMID 18936466·J Clin Oncol·2008
8-other
Ad-MDA-7; INGN 241: a review of preclinical and clinical experience.
PMID 18774929·Expert Opin Biol Ther·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11277 VERNON PL STE 200
MEADVILLE, PA 16335 - Phone
- (814) 724-1252
Quick Facts
- NPI
- 1295185130
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile